Effect of aberrant fructose metabolism following SARS-CoV-2 infection on colorectal cancer patients' poor prognosis
Jiaxin Jiang,Xiaona Meng,Yibo Wang,Ziqian Zhuang,Ting Du,Jing Yan
DOI: https://doi.org/10.1371/journal.pcbi.1012412
2024-09-29
PLoS Computational Biology
Abstract:Most COVID-19 patients have a positive prognosis, but patients with additional underlying diseases are more likely to have severe illness and increased fatality rates. Numerous studies indicate that cancer patients are more prone to contract SARS-CoV-2 and develop severe COVID-19 or even dying. In the recent transcriptome investigations, it is demonstrated that the fructose metabolism is altered in patients with SARS-CoV-2 infection. However, cancer cells can use fructose as an extra source of energy for growth and metastasis. Furthermore, enhanced living conditions have resulted in a notable rise in fructose consumption in individuals' daily dietary habits. We therefore hypothesize that the poor prognosis of cancer patients caused by SARS-CoV-2 may therefore be mediated through fructose metabolism. Using CRC cases from four distinct cohorts, we built and validated a predictive model based on SARS-CoV-2 producing fructose metabolic anomalies by coupling Cox univariate regression and lasso regression feature selection algorithms to identify hallmark genes in colorectal cancer. We also developed a composite prognostic nomogram to improve clinical practice by integrating the characteristics of aberrant fructose metabolism produced by this novel coronavirus with age and tumor stage. To obtain the genes with the greatest potential prognostic values, LASSO regression analysis was performed, In the TCGA training cohort, patients were randomly separated into training and validation sets in the ratio of 4: 1, and the best risk score value for each sample was acquired by lasso regression analysis for further analysis, and the fifteen genes CLEC4A , FDFT1 , CTNNB1 , GPI , PMM2 , PTPRD , IL7 , ALDH3B1 , AASS , AOC3 , SEPINE1 , PFKFB1 , FTCD , TIMP1 and GATM were finally selected. In order to validate the model's accuracy, ROC curve analysis was performed on an external dataset, and the results indicated that the model had a high predictive power for the prognosis prediction of patients. Our study provides a theoretical foundation for the future targeted regulation of fructose metabolism in colorectal cancer patients, while simultaneously optimizing dietary guidance and therapeutic care for colorectal cancer patients in the context of the COVID-19 pandemic. While diagnostic testing enables speedy detection of COVID-19 cases, the paucity of indicators for post-diagnostic risk assessment, particularly in cancer patients, hinders decisions for therapy allocation and cascade. The combination of clinical data with a vast array of omics technologies enables the development of new methods for describing complex patient metabolism and its relationship to clinical outcomes, particularly fructose metabolism, which has been shown to be closely associated with the progression of colorectal cancer. Although indicative of adverse outcomes in cancer patients, biomarkers of aberrant fructose metabolism may indicate systemic metabolic changes in COVID-19 patients. Moreover, the development of prognostic models of fructose metabolism showed COVID-19-specific prognostic indicators and disease-specific pathways of CRC, including aberrant fructose metabolism. In conclusion, targeting fructose metabolism is a novel therapeutic strategy that should be investigated in COVID-19 patients with CRC. This study aimed to investigate the differential expression and clinical significance of fructose metabolism-related genes in CRC patients infected with SARS-CoV-2, to investigate the effect of fructose metabolism changes on CRC development, to provide theoretical basis for further targeted regulation of fructose metabolism in CRC patients, and to help optimize the dietary guidance and clinical management of these patients.
biochemical research methods,mathematical & computational biology